• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

2024 Prediction from Jeffrey Casberg, M.S., RPh


Casberg is Vice President of Clinical Pharmacy at IPD Analytics LLC and a member of the Managed Healthcare Executive editorial advisory board. He predicts that "payers will tighten" in 2024.

We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Jeffrey Casberg, M.S., RPh had to say:

“There will be increased trend toward transparency in the pharmacy benefit management industry, but the net result will

likely be little or no savings to employers or government payers. Negotiated Medicare drug prices under the Inflation Reduction Act don’t go into effect until 2026. Even so, the prospect of negotiated prices will start to affect Medicare and commercial payers’ formulary management in 2024. This will be the second year that Humira (adalimumab) biosimilars will be on the market. Compared to some high year two expectations, uptake will be lower than even modest prediction.

With Wegovy (semaglutide) and Zepbound (tirzepatide) approved by the FDA and on the market, payers will be working to tighten glucagon-like peptide 1 (GLP-1) inhibitor coverage criteria in 2024 as utilization continues to ramp up. We’re also going to see increased pressure on federal and state payers to cover weight loss drugs.

The drug shortages have been a problem for several years, especially in the hospital space, and they will continue next year. It is a problem with many different causes. None of them yield to easy answers and they won’t be solved in 2024.”

Related Videos
Video 9 - "Denial of Coverage in Fertility Care"
Video 8 - "Risks of Miscarriage and Multiple Births Associated with Fertility Care"
Video 7 - "Fertility Preservation: Egg Freezing Versus Embryo Freezing"
Video 6 - "Family Building Costs, Barriers, and Dropout Rates Associated with Fertility Care"
Video 5 - "Closing Payer Gaps and Improving Fertility Care Access"
Video 4 - "Increasing Employer Coverage and Maximizing Fertility Benefits "
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Video 3 - "Improving IVF Success Rates & Utilizing AI in Fertility Health Care"
Video 2 - "Holistic Fertility Management and Payer Collaboration"
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Related Content
© 2024 MJH Life Sciences

All rights reserved.